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Abstract
Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The 
economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this 
study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and 
urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method 
(monitoring of serum creatinine (sCr) level).
Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based di-
agnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of 
sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility measurement included in the analysis was quality-adjusted 
life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER).
Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and 
sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagno-
stic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY.
Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac 
surgery.
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Introduction
Children undergoing cardiac surgery for congeni-
tal heart disease (CHD) are at high risk to experi-
ence the development of acute kidney injury (AKI) 
in the immediate postoperative period (1-4) due to 
hypotension, inflammation, and nephrotoxic med-
ication use (4). The incidence of AKI is in the range 
of 5-50% with an associated mortality of 20-79%, 
depending on the AKI definition used (2). Retro-
spective studies also suggest that the presence of 
AKI after cardiac surgery may be associated with 
the development of chronic kidney disease (CKD) 
(5-7). According to data from the North American 
Pediatric Renal Trials and Collaborative Studies 
(NAPRTCS) on children with CKD stages 2–4 inci-
dence rate of end-stage renal disease (ESRD) in the 
1 year is 17% and after three years is 39% with me-
dian time to ESRD of 4.5 years (8). However, the 
outcome of children with ESRD is highly depend-
ent upon availability of health care resources and 
applied renal replacement therapy (RRT). The aver-
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age life expectancy of young adults who started 
RRT with a functioning graft during childhood is 
63 years, while average life expectancy of young 
adults who remain on dialysis is 38 years (9). If to 
these dramatic data, we add extremely high costs 
of treatment for AKI and CKD patients, it is clear 
that there is a need to ensure a better outcome for 
AKI patients and better targeting of scarce re-
sources for health care systems.
Increase in serum creatinine (sCr) concentration is 
used for the diagnosis of AKI. Unfortunately, in-
crease in sCr concentration may be delayed com-
pared to the already existing renal impairement 
and therefore administered therapy may be less ef-
fective. According to the literature, more than half 
of pediatric CHD patients (53%) develop AKI within 
the first 24h after the operation, and even 97.7% by 
48h (2). Delayed diagnosis of AKI with sCr affects not 
only the worse outcome of AKI patients, but  also 
higher resource use for health care systems. 
On the other side, many new biomarkers offer 
promise for early detection of AKI (10-12). Since the 
ischemic stress during cardiopulmonary bypass 
(CPB) is the dominant etiological factor of AKI that 
affects proximal tubular integrity, in this study we 
examined the biomarkers that depend directly or 
indirectly on the function integrity of the proximal 
tubules: neutrophil gelatinase-associated lipocalin 
(NGAL), liver fatty acid-binding protein (L-FABP), 
cystatin C (CysC). NGAL, which is synthesized in 
the systemic and renal pool, secreted by the thick 
ascending limb of loop of Henle and collecting 
ducts, is largely reabsorbed in the proximal tu-
bules by efficient megalin-dependent endocytosis 
(10). Thus, increase in urine excretion of NGAL is 
likely to occur when there is an injury to proximal 
renal tubular epithelium and/or increased synthe-
sis in the distal nephrons. Because L-FABP is ex-
pressed predominantly in proximal tubules, tubu-
lar stress that causes AKI may up regulated renal L-
FABP expression and then accelerates urinary ex-
cretion of L-FABP from proximal tubules (11). CysC 
is almost completely reabsorbed and catabolized 
by the normal proximal tubules. When they are 
damaged as happen during CPB, the concentra-
tion of CysC increases in serum (12). According to 
the study Peco et al., serum CysC (sCysC), urine 
NGAL (uNGAL) and urine L-FABP (uL-FABP) may 
rise as soon as 2h after cardiac surgery and 24 to 
48h before sCr increases (13). Based on this, we as-
sumed that their measurement may facilitate the 
faster recognition of AKI and promote earlier insti-
tution of preventive therapies. In addition to as-
sessment of effectiveness, there is a need to calcu-
late the costs of new diagnostic strategies. 
Potential benefits from the use of new biomarkers 
must be balanced against the additional costs in-
cluding test cost, the cost of stay in hospital and 
the costs of all clinical outcomes. The most com-
monly used method for economic evaluation is in-
cremental cost-effectiveness analysis (ICEA). It 
compares at least two strategies against each oth-
er regarding expected costs and expected health 
outcomes (14). The health outcomes are usually 
expressed as quality-adjusted life years (QALY). 
QALY takes into account both the quantity and 
quality of life generated by healthcare interven-
tions (15). Economic evaluations are often based 
on the use of decision analytic modelling, decision 
trees and Markov models. Markov models are use-
ful for diseases in which events may occur repeat-
edly over time, when the timing of events is im-
portant, and when important events may happen 
more than once (14). 
Therefore, we developed a decision analytical 
model to calculate incremental cost-effectiveness 
of different biomarker-based diagnostic strategies 
which can be used in the clinical practice com-
pared to current diagnostic strategy. Since the 
economic impact of a biomarker-based diagnostic 
strategy is little known, the aim of this study was 
to compare cost and effectiveness of novel kidney 
biomarkers and to perform the cost-effectiveness 
analysis of using sCysC, uL-FABP and uNGAL for 
the diagnosis of AKI in children after cardiac sur-
gery compared with current diagnostic method 
(monitoring of sCr level).  
Materials and methods
Base case model 
The model simulates the detection of AKI after car-
diac surgery, treatment of AKI patients, progres-
sion of AKI to CKD, and finally treatment of CKD in 
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a cohort of patients younger than 18 years until 
each member of the cohort dies or reaches 100 
years of age. At first, we created the decision tree 
to depict different strategies for the diagnosis of 
AKI in pediatric patients following CPB: using of 
standard strategy (monitoring of sCr level) or alter-
native diagnostic strategies (application of three 
kidney biomarkers: sCysC, uNGAL and uL-FABP). 
Decision analytical model is presented in Figure 1.
Standard monitoring strategy
Probabilities for AKI development detected with 
sCr and in-hospital mortality were calculated from 
the study Peco et al. (13). That study included rela-
tively homogenous cohort of 112 pediatric sub-
jects who underwent CPB due to CHD. The prima-
ry outcome was AKI development, defined as at 
least 25% decrease in the estimated creatinine 
clearance (eCCl) from pre-operative baseline at 
48h after surgery, where eCCl was assessed ac-
cording to formula of Schwartz et al. (16). Based on 
that, patients were divided into the AKI and non-
AKI groups. The AKI was developed in 18 patients 
(16.1%). Secondary outcome included severity of 
AKI based on the pediatric modified RIFLE (Risk, In-
jury, Failure, Loss, End-Stage Kidney Disease) (pRI-
FLE) criteria for diagnosis of AKI (17). pRIFLE scores 
were calculated using eCCl criteria with “Risk (R)” 
defined as eCCl decrease of 25% from baseline, 
“Injury (I)” defined as eCCl decrease of 50%, and 
“Failure (F)” defined as eCCl decrease of 75% or 
need for dialysis. 
Figure 1. Decision analytical model used to assess new biomarkers serum cystatin C (sCysC), urine neutrophil gelatinase-associated 
lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of acute kidney injury (AKI) in children after 
cardiac surgery compared with standard monitoring (serum creatinine (sCr) level). Chronic kidney disease (CKD); end-stage renal dis-
ease (ESRD); true positive (TP); false positive (FP); true negative (TN); false negative (FN).
SCys C elevated – TP (treatment)
SCys C elevated – FP (treatment)
uNGAL elevated – TP (treatment)
uNGAL elevated – FP (treatment)
uL-FABP elevated – TP (treatment)
uL-FABP elevated – FP (treatment)
SCys C normal – FN (no treatment)
SCys C normal – TN (no treatment)
uNGAL normal – FN (no treatment)
uL-FABP normal – FN (no treatment)
uL-FABP normal – TN (no treatment)
uNGAL – TN (no treatment)
Monitor with sCys C
Monitor with uNGAL
Monitor with uL-FABP
standard monitoring
no AKI
no AKI
no AKI
no AKI
AKI
AKI
AKI
AKI
other AKI
risk
discharge
discharge
discharge
survival
survival
injury
death
death
death
death
survival
death
death
failure
transplatation
ESRD
CKD
(1–4 stages)
no CKD
death
http://dx.doi.org/10.11613/BM.2015.027 Biochemia Medica 2015;25(2):262–71 
  265
Petrovic S. et al. Economic evaluation of AKI biomarkers in children
Se Sp TP FN TN FP
uL-FABP 1 0.86 1 0 0.86 0.14
sCys C 0.54 0.82 0.56 0.44 0.82 0.18
uNGAL 0.63 0.60 0.61 0.39 0.61 0.39
Se - sensitivity; Sp - specificity; TP - true positive; FP - false positive; TN - true negative; FN - false negative; uNGAL - urine neutrophil 
gelatinase-associated lipocalin; uL-FABP - urine liver fatty acid-binding protein; sCysC - serum cystatin C.
Table 1. Diagnostic characteristics of new biomarkers.
Furthermore, we also included probabilities for 
progression of renal disease and postdischarge 
death in patients who had an AKI episode. Here 
we used data from the few studies of monitoring 
transition from AKI to CKD that have been imple-
mented until now (6,7).
Alternative diagnostic strategies
In alternative diagnostic strategies, AKI diagnose 
was based on clinical application of three kidney 
biomarkers: sCysC, uNGAL and uL-FABP, which 
showed good accuracy for early AKI diagnosis af-
ter cardiac surgery. Based on the data from the 
study Peco et al. (13) for sensitivity (Se) and speci-
ficity (Sp) we calculated the following parameters: 
true positive (TP), false positive (FP), true negative 
(TN) and false negative (FN) for alternative strate-
gies with sCysC, uNGAL and uL-FABP at 2h after 
surgery (Table 1).
Markov model
If the AKI is present, patient will enter the Markov 
model, which was created to compare the lifetime 
cost associated with using of sCysC, uNGAL and 
uL-FABP with sCr for the diagnosis of AKI. In our 
study, the Markov model consists of following 
health states: no CKD, CKD (1-4 stages), ESRD, 
transplantation and death. Transition probabilities 
were taken from the cited sources (6-8,13,18-20), 
either as direct value or calculated on the one year 
probability assuming the constant rate (21). All 
Probabilities that were used in this model and 
their sources are listed in Table 2. 
QALYs are calculated by multiplying the duration 
of time spent in a health state by utility score. Util-
ity score was defined as value between 0 and 1, 
where 0 represents death and 1 represents a 
health state equal to perfect health (15). We ob-
tained utility data from the Cost-Effectiveness 
Analysis (CEA) registry database (22), and the val-
ues are also presented in the Table 2. 
TreeAge Healthcare module version 1.5.2 (TreeAge 
Software, Inc, Williamstown, USA) was used to cre-
ate the model and conduct the sensitivity analysis. 
The TreeAge is the software used in decision anal-
ysis in order to perform a comparative analysis of 
alternative courses of action.
Previous therapy as a result of the earlier diagnosis 
with sCysC, uL-FABP and uNGAL was assumed to 
be associated with improved clinical outcome. It 
was represented by an assumed percentage (25%) 
of AKI patients for whom outcome was improved 
by earlier institution of preventive therapies 
(Table 2) (23,24).
Costs
The cost-effectiveness analysis was performed 
from a third-party payer perspective. Due to that, 
only direct medical costs were taken into consid-
eration. Costs of diagnostic testing, hospitaliza-
tions, nephrologist consultation and RRT were ex-
pressed in dollars ($) (25-30). Costs are summarized 
in Table 3. 
The consumed diagnostic procedures included 
measurements of sCr, sCysC, uNGAL and uL-FABP 
concentrations. In the study Peco et al. (13), sCr lev-
els were measured by a modification of the kinetic 
Jaffe reaction, so we used price list for sCr assay 
from St. John Hopkins hospital (25), since this 
method is generally used in laboratories. sCysC, 
uNGAL and uL-FABP were assayed using human-
specific commercially available enzyme-linked im-
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specialist visits, screening and diagnosis of CKD 
was used from the study Hoerger et al. (28). 
All costs and outcomes were discounted by 3%. 
The discounting was performed due to the differ-
ential timing of costs and consequences of the 
compared strategies. The 3% discount rate was 
used in line with the recomendation from the US 
Public Health Service Panel on Cost-Effectiveness 
in Health and Medicine (14).
Cost-effectiveness analysis
The results of the analysis are presented as the in-
cremental cost-effectiveness ratio (ICER) which 
represents additional costs per additional effec-
tiveness of each alternative diagnostic strategy 
compared to “monitoring of sCr level”. Cost-effec-
tiveness threshold was set at $50000 per QALY 
gained, as recommended for the United States 
Variable Value Source
Probabilities
Development of AKI in pediatric patients during CS 0.16 (13)
Patients classified as pRIFLE-R 0.56 (13)
Patients classified as pRIFLE-I and pRIFLE-F 0.22 (13)
In-hospital mortality among pRIFLE-R patients 0.10 (13)
In-hospital mortality among pRIFLE-I and pRIFLE-F patients 0.25 (13)
Survival for AKI patients (3-5 years)* 0.80 (6)
Development of CKD among AKI patients 0.10 (7)
Development of CKD among AKI patients after early therapy 0.075 (23,24)
Progression to ESRD among children with CKD stages 2–4 (3 years)* 0.39 (8)
Transplantation after the development of ESRD (3 years)* 0.75 (18)
Mortality in pediatric dialysis and transplant patient (5 years)* 0.08 (19)
Annual mortality varies by age (20)
Utilities
No CKD (children population) 0.93 (22)
CKD 0.85 (22)
ESRD 0.61 (22)
Transplantation 0.74 (22)
Death 0
AKI - acute kidney injury; CKD - chronic kidney disease; CS - cardiac surgery; ESRD - end-stage renal disease; pediatric modified RIFLE 
(Risk, Injury, Failure, Loss, End-Stage Kidney Disease) criteria (pRIFLE): “Risk (R)”, “Injury (I)”, “Failure (F)”. 
* - all transition probabilities were calculated on the one year probabilty assuming the constant rate. 
Table 2 . Input variables used in base-case analysis.
munoassays (ELISA) (R&D Systems, Inc., Minneapo-
lis, Minesota), on ELISA reader (LKB, Vienna, Aus-
tria) according to the manufacturer’s recommen-
dations. Since used ELISA kits contained the entire 
material required for the work, we calculated pric-
es for biomarker assays only from charges for ELI-
SA kits (26). The cost of the assay included con-
sumption for calibration (7 points) and a reagent 
blank test, as was done in duplicate. In addition, it 
was calculated that each analysis was performed 
in triplicate.
In order to assess the viability of new biomarkers 
of AKI and the availability of incidence data for 
transition from AKI to CKD, we used cost for AKI 
threatment for pediatric populations in the United 
States. The Kids’s Inpatient Database (KID) was de-
signed to identify and track trends in hospital utili-
zation, access, cost, and outcome across the Unit-
ed States (27). Furthermore, cost for generalist and 
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study results. Probabilistic sensitivity analysis was 
used to test the uncertainty of the model. Ten 
thousand simulations were performed. In every 
simulation, each input parameter (probability, cost 
and utility) was sampled from the defined distri-
bution of that parameter (21). The discount rate 
was varied from 0% (undiscouted) to 5% (14).
Results
Base-case results compared lifetime costs and as-
sociated QALY of current diagnostic method (mon-
itoring of sCr level) with cost and QALY of new bio-
marker-based diagnostic strategies (Table 4). The 
cost-effectiveness ratios for all strategies were 
quite low, between $1485/QALY for sCr and $3579/
QALY for uNGAL. ICER for all new biomarkers were 
well below the set threshold of $50000/QALY. 
However, uNGAL and sCys C were dominated 
strategies, meaning strategies with higher costs 
and lower effectiveness compared to uL-FABP 
strategy. uL-FABP added 1.43 QALY compared to 
current diagnostic method at an additional cost of 
$8521.87 per patient. Therefore, the ICER for uL-
FABP compared to sCr was $5959.35/QALY.
Sensitivity analysis results
Scatterplot of cost and QALY differences for new 
biomarkers are presented at the Figure 2 and Fig-
ure 3. The diagonal line represents a cost-effec-
tiveness threshold of $50000/QALY gained. The 
probabilistic sensitivity analyses indicated that the 
uL-FABP strategy was cost-effective for all 10000 
simulations at the specified threshold (point be-
low and to the right of the line) (Figure 2). For two 
Cost item Cost (dollars ($)) Source
Cr assay 14 $ (25)
CysC ELISA assay 18.94 $ (26)
NGAL ELISA assay 17.81 $ (26)
L-FABP ELISA assay 24.38 $ (26)
AKI (after cardiac surgery) 18323 $ (27)
CKD screening first visit 80.32 $ (28)
CKD screening afterward if first positive 62.64 $ (28)
CKD diagnosis (GFR<60) 214.75 $ (28)
Annual specialist follow-up (GFR < 60) 77.28 $ (28)
Annual generalist visits (3 per year) 120.48 $ (28)
CKD in children 38893 $ (27)
ESRD first year 72348 $ (29)
ESRD subsequent year 59963 $ (29)
Kidney transplant in children 70193 $ (27)
Maintenance post-transplant 13749 $ (30)
AKI - acute kidney injury; CKD - chronic kidney disease; ESRD 
- end-stage renal disease; GFR - glomerular filtration rate; Cr - 
creatinine; NGAL - neutrophil gelatinase-associated lipocalin; 
L-FABP - liver fatty acid-binding protein; CysC - cystatin C; ELISA 
- enzyme-linked immunoassays.  
Table 3. Direct medical costs used in model.
Strategy Cost ($) Incremental cost ($)
Effectiveness 
(QALY)
Incremental 
effectiveness 
(QALY)
C/E ($/QALY) ICER ($/QALY)
sCr assay 5607.50 - 3.78 - 1483.46 -
uL-FABP assay 14126.37 8521.87 5.21 1.43 2711.39 5959.35
sCysC assay 15303.57 9696.07 5.15 1.37 2971.57 7077.42
uNGAL assay 18462.65 12855.15 5.16 1.38 3578.03 9315.33
QALY - quality-adjusted life years; sCr - serum creatinine; uNGAL - urine neutrophil gelatinase-associated lipocalin; uL-FABP - urine 
liver fatty acid-binding protein; sCysC - serum cystatin C. 
Table 4. ICER of base-case model (all strategies compared to current diagnostic method – monitoring of sCr level).
health care system (31). If the ICER is lower than the 
set threshold, the strategy is considered to be 
cost-effective.
Sensitivity analysis
Sensitivity analysis was conducted for factors that 
could possibly restrict the generalisability of the 
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Figure 2. Cost-effectiveness scatterplot of incremental costs 
and incremental effects of urine liver fatty acid-binding protein 
(uL-FABP) vs. current diagnostic method (serum creatinine (sCr) 
level).
Figure 3. Cost-effectiveness scatterplot of incremental costs and incremental effects of urine neutrophil gelatinase-associated lipo-
calin (uNGAL) and serum cystatin C (sCysC) vs. current diagnostic method (serum creatinine (sCr) level).
other biomarkers (uNGAL and sCys), sensitivity 
analysis shows ICER was above the set threshold 
(points above and to the left of the line (Figure 3). 
Discussion
Because health care budgets and resources of all 
systems have become more restrictive, many have 
increasingly supported cost-effectiveness analysis 
and related analytical methods to assess the im-
pact of new diagnostic and therapeutic interven-
tions to facilitate efficient allocation of scarce re-
sources (23).
The results of our study show  that analysed bio-
marker-based diagnostic strategies for AKI are 
cost-effective compared to current diagnostic 
method. However, uNGAL and sCys C strategies 
yielded higher costs and lower effectiveness com-
pared to uL-FABP strategy. Additional QALY and 
cost for uL-FABP compared to current diagnostic 
method were 1.43 and $8521.87 respectively. The 
ICER for uL-FABP compared to sCr was $5959.35/
QALY and that was lower than specified threshold 
($50000/QALY). Therefore, our results suggest that 
the use of uL-FABP would represent an economi-
cally advantageous strategy for early diagnosis of 
AKI in children after cardiac surgery. Higher price 
for uL-FABP assay compared to sCr, and even sCysC 
and uNGAL assays, is fully compensated by its bet-
ter diagnostic characteristics (Se and Sp) for early 
detection of AKI, which would enable timely and 
more efficient treatment of patients. This would 
lead to significantly improved outcomes for AKI 
patients and finally lower long-term resource con-
sumption. Shaw and colleagues (23) applied cost-
effectiveness analysis and compared uNGAL to 
standard monitoring in 67-year-old male patient 
undergoing coronary artery bypass graft surgery. 
According to results from that study uNGAL was 
cost-effective strategy and the differences be-
tween costs and QALYs increased as the treatment 
effect rose (23). Difference in results beetwen our 
study and Shaw et al. study was in chosen popula-
tion and number of examined parameters. Chil-
dren after cardiac surgery are an ideal type of pa-
tient in whom studying of AKI biomarkers is possi-
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ble without the influence of co morbidities that 
complicate similar studies in adults, such as diabe-
tes, chronic hypertension and atherosclerosis. 
Since this is the first economic evaluation of CysC 
and L-FABP, there are no data available for compar-
ison to our study.
In our study sensitivity analysis was performed to 
determine how changes in values for the variables 
would affect the findings. In this way, we varied 
data for the incidence of AKI development after 
cardiac surgery with an associated mortality, since 
these data differ considerably between studies, 
primarily because of the different criteria that was 
used to set AKI diagnosis. Also we varied diagnos-
tic characteristics of assays (Se and Sp), since our 
analysis is based on the results of one study, Peco 
et al. (13). Using the data of several studies about 
diagnostic characteristics of assays for the eco-
nomic study is not adequate, because the various 
studies used assays from different manufacturers 
and therefore different prices. Generalisability of 
the study results was confirmed because uL-FABP 
remained dominant throughout a wide range of 
values for the underlying variables. After applied 
sensitivity analysis, ICER values for uNGAL and sCys 
were above the set threshold and that confirmed 
that uL-FABP have the best cost-effectivness 
among analysed biomarkers (Figure 3).
In addition to the potential application of uL-FABP 
for the early diagnosis of AKI after cardiac surgery 
we should mention the following: urinary diagnos-
tic has several advantages, including the noninva-
sive nature of sample collection, which is very im-
portant in pediatric populations. Furthermore, uL-
FABP may be also used to predict severity of AKI, 
as it distinguish between R and severe AKI catego-
ries, also uL-FABP shows the best correlations with 
CPB and aorta clamp (AC) time, risk adjustment for 
congenital heart surgery (RACHS) score (13). There-
fore, our recommendation is development of algo-
rithm that will based on clinical parameters (pa-
tient age, CPB and AC time, RACHS score), that 
would enhance assessment of risk for AKI develop-
ment. A high score in this algorithm and increased 
value of uL-FABP at 2h after surgery could perform 
selection of patients in whom treatment should 
be applied immediately. Applicability of the pro-
posed algorithm should be tested in properly de-
signed clinical trials.
Our finding highlights the importance of effective 
diagnostic tests, which accurately selects patients 
with AKI who need early intervention or modifica-
tion of therapy to mitigate severe and permanent 
kidney injury, as opposed to unaffected patients 
who will not benefit. It is clear that early diagnosis 
of AKI requires a good and not expensive screen-
ing test with high Se and small percentage of FN 
results, because it is important not to miss any ill 
person (32). In addition, it is important that applied 
analysis provides a rapid and accurate results. In 
this context, unlike uNGAL and sCys C biomarkers 
that have already developed rapid point-of-care 
(POC) tests, L-FABP biomarker still not have possi-
bility of this type of analysis. Development of POC 
test for uL-FABP is desirable, because these tests 
have several advantages (rapid test results and 
smaller volumes of specimen needed for testing) 
(33).
AKI is a major side effect of other medical proce-
dures and can result from insults ranging from is-
chemia reperfusion injury following CPB surgery 
or renal transplant to damage from nephrotoxic 
agents such as contrast used or cysplatin. We be-
lieve that the application of biomarkers could im-
prove the diagnosis of AKI and reduce costs addi-
tionally in these clinical conditions, but it has to be 
proven in especially designed studies. 
Findings of our study can also provide important 
information for pharmacological research studies. 
Results in this field would certainly contribute to 
the better outcome of patients with AKI and ena-
ble significant savings as compared to expensive 
dialysis. There are already encouraging results in 
the form of application of high-dose fenoldopam, 
a selective dopamine-1 receptor, that positively af-
fect on renal function and organ perfusion during 
CPB in infants with CHD (24).
The main limitation of our study is method used to 
determine the concentration of biomarkers (ELI-
SA), because if we are talking about early diagno-
sis of AKI, it is certainly not desirable to wait for the 
result of biomarkers for 6-7 h. Also, our study in-
cluded only direct medical costs since the study 
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perspective was a third-party payer. No indirect 
cost of CKD were included in the analysis. 
Conclusions
Our results suggest that among all examined bio-
markers only uL-FABP had acceptable ICER and the 
use of uL-FABP would represent cost-effective 
strategy for early diagnosis of AKI in children after 
cardiac surgery. The higher prices for commercial 
uL-FABP test will not change the conclusion of our 
study because the sensitivity analysis demonstrat-
ed that significant variations in the price will not 
influence on ICER value. 
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